Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Malwinder Singha

Vascular & Interventional Radiology Rancho Cucamonga, CA Medical Doctor

NPI 1972558203 CMS profile 180296

8283 Grove Ave Ste 207A, Rancho Cucamonga, CA 91730

Open in the dashboard

General payments

$251,580

368 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Malwinder Singha of Rancho Cucamonga, CA is reported in the CMS Open Payments database as having received $251,580 across 368 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,025 50
2024 General $61,836 65
2023 General $102,661 81
2022 General $57,472 54
2021 General $5,567 41
2020 General $3,726 23
2019 General $16,293 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Malwinder Singha
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Malwinder Singha were reported at $4,025. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Malwinder Singha Vascular & Interventional Radiology median Middle half National median
2019 $16,293 $422 $125–$1,555 $163
2020 $3,726 $200 $68–$652 $114
2021 $5,567 $280 $99–$866 $132
2022 $57,472 $433 $137–$1,497 $149
2023 $102,661 $506 $152–$2,019 $160
2024 $61,836 $556 $175–$1,930 $164
2025 $4,025 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $197,841 42 payments
  2. Cardiovascular Systems Inc. $21,294 53 payments
  3. Cook Incorporated $15,690 3 payments
  4. Cook Medical LLC $3,397 77 payments
  5. Nevro Corp. $2,573 24 payments
  6. Nalu Medical, Inc. $1,333 18 payments
  7. Terumo Medical Corporation $1,332 11 payments
  8. Merit Medical Systems Inc $1,267 7 payments
  9. Medtronic, Inc. $1,252 12 payments
  10. Smith+Nephew, Inc. $1,037 21 payments
  11. Other $4,565 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $196,750 9 payments
  2. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $17,200 6 payments
  3. Food and Beverage $15,642 330 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,890 2 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $5,550 3 payments
  6. Travel and Lodging $4,167 16 payments
  7. Education $1,081 1 payment
  8. Consulting Fee $300 1 payment
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $196,750 9 payments
  2. Peripheral Orbital Atherectomy System $13,308 20 payments
  3. Diamondback Peripheral $7,275 28 payments
  4. Zilver Vena $6,930 1 payment
  5. Zilver PTX $5,267 16 payments
  6. Cook Medical Zilver PTX $4,945 7 payments
  7. Senza $1,374 22 payments
  8. Nalu Neurostimulation System $1,333 18 payments
  9. SwiftNINJA Sterble Cor Micro $1,267 7 payments
  10. Embosphere Microspheres $1,267 7 payments
  11. Other $12,390 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

995

Median for Interventional Radiology: 38

Drug cost

$147,501

Median for Interventional Radiology: $333

Branded share of claims

72.5%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 100 $71,639
Xarelto Rivaroxaban Brand 80 $52,094
Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam Brand 59 $9,113
Vancomycin Hcl Generic 58 $6,297
Clopidogrel Clopidogrel Bisulfate Brand 384 $4,000
Meropenem Generic 17 $1,416
Pregabalin Generic 47 $952
Gabapentin Generic 19 $495
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $376
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 55 $362

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 104 billing codes

Paid by Medicare

$6,214,894

Of which drugs: $2,771,986

Medicare patients

287

Average age 73

Services billed

28,833

165 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Arthritis 56%
Chronic kidney disease 44%
Ischemic heart disease 36%
Heart failure 30%
Depression 22%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, alteplase recombinant, 1 mg J2997 Office 66 451 $31,811
Injection, fentanyl citrate, 0.1 mg J3010 Office 101 1,786 $1,338
Injection, propofol, 10 mg J2704 Office 103 13,293 $1,153
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 92 6,943 $720
Injection, ketorolac tromethamine, per 15 mg J1885 Office 64 156 $76
Injection, midazolam hydrochloride, per 1 mg J2250 Office 80 330 $36
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 62 396 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $42
$42 100 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

368 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record